Dutch nationwide study of eligibility and real-world use of adjuvant chemotherapy in colon cancer

Adjuvant chemotherapy (ACT) improves survival in patients with resected stage III and high-risk stage II colon cancer, yet its use in routine clinical practice remains variable. A population-based study in The Netherlands evaluated real-world adherence to guideline-recommended ACT. Data from the Netherlands Cancer Registry (NCR, 2005-2020) were used to identify adults with nonmetastatic colon cancer who underwent surgical resection. Eligibility for ACT was defined as pT4N0 or node-positive disease according to Dutch guidelines and the available NCR variables. Among 44,471 patients, 22,050 (49.6%) were pathologically eligible for ACT. Among these patients, 12,748 (57.8%) initiated treatment. Among ineligible patients, 2.6% received ACT, Non-adherence was strongly associated with advance age (29.9% of patients aged 75 years or older without comorbidities received ACT), comorbidity, female sex, right-sided tumor, and non-elective surgery (all p<0.001). Younger patients were more likely to receive ACT despite pathological ineligibility. Adherence also varied by hospital type, with lower adherence in teaching and academic hospitals compared with general hospitals (p<0.001). The authors conclude that in this nationwide cohort, guideline-recommended ACT was frequently not delivered to pathologically ineligible patients.